Results from a study last year suggest that people with immune-mediated inflammatory diseases (IMIDs) respond well to vaccination and that COVID-19 vaccines in Canada are highly effective in protecting them. against hospitalization due to COVID-19.
These patients include people living with rheumatoid arthritis, psoriasis and inflammatory bowel disease.
A joint study by scientists from the Sunnybrook Health Sciences Center in Toronto and the Research Institute of McGill University Health Center (MUHC) in Montreal indicates that mRNA vaccines are effective at 92% to 97% against serious consequences. of COVID-19 for living people. along with these inflammations.
They often undergo immunosuppressive treatments, which can compromise their immune system and make them more susceptible to serious illness from COVID-19.
Research has observed a slight decrease in effectiveness against infection over time, but vaccination remained highly effective even beyond 120 bears after the second dose and rebound after the third dose.
Jessica Widdifield, lead author of the study and scientist at the Sunnybrook Center, pointed out that the effectiveness of vaccines for Canadians living with immune-mediated inflammatory diseases has not been studied in depth. to date, mainly because they have not been included in clinical trials of Vaccines against covid19. In his opinion, the results of the study are encouraging.
Dr. Sasha Bernatsky, lead author of the study and a professor in the Department of Medicine at McGill University Health Center, added that the medications patients need to manage their illnesses can increase their susceptibility to infection. According to him, the results of the study compiled up to last November show that it is possible for these people to get adequate protection by vaccination against COVID-19.
The study shows that in the groups of patients concerned, the effectiveness of vaccines against infection was found to be higher in those who received Spikevax from Moderna than in those who received Comirnaty from Pfizer-BioNTech .
In Canada, more than 7 million people over the age of 16 live with an immune-mediated inflammatory disease.
The study was funded by the COVID-19 Immunity Task Force (TICT) of the Government of Canada. His results are published in The Lancet.
Source: Radio-Canada
